Toralgen is a preclinical stage biopharmaceutical company focused on the development and commercialization of human therapeutics. Our unique poly-bile nanoparticle platform eliminates the challenges of oral delivery in one simple to fabricate nanopill. These nanopills also localize delivery of drug agents and potentially improve efficacy and safety of a wide range of therapies. Toralgen currently has two candidates in preclinical testing for oral delivery of diabetes agents. Toralgen collaborates with leading pharmaceutical companies to apply our targeted delivery technology across a wide range of therapeutic areas, molecule types and routes of administration.
The platform's intrinsic properties lead it to be the perfect carrier for advanced autoimmune treatments including antigen specific tolerance induction.
Toralgen offers effective encapsulation of peptides and anti-inflammatory agents and delivers with high bioavailability